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Value (SUV) was measured. The maximum SUV were compared with 
each histologic subtype and stage. 
Results: All 35 lesions showed various levels of increased FDG 
uptake. Table shows the relationship between histologic subtype and 
maximum SUV. With regard to stage, 10 patients were in stage I, 
8 were in stage II, 5 were in stage III, and 2 were in stage IVa. The 
maximum SUV were 4.0 ± 1.08 (range, 2.6-5.2) for stage I, 5.1 ± 2.07 
(range, 3.8-9.9) for stage II, 5.9 ± 2.57 (range, 3.5-8.9) for stage III, 
and 3.8 ± 1.27 (range, 2.9-4.7) for stage IVa. The differences in the 
maximum SUV between ﬁve histologic subtypes were statistically sig-
niﬁcant (p=0.000). On the other hand, no signiﬁcant differences were 
found between each stage.
Conclusions: Our results suggest that FDG-PET is useful for predict-
ing the histologic subtype in thymic epithelial tumors. Further studies 
are needed to evaluate other clinical usefulness of FDG-PET for thymic 
epithelial tumors.
  Maximum SUV
Histologic subtype No. of Patients Mean ± SD Range
A 4 3.3 ± 0.75 2.6-4.3
AB 8 3.9 ± 0.81 3.0-5.2
B1 4 4.7 ± 0.82 4.0-5.7
B2 3 5.1 ± 0.43 4.7-5.1
B3 2 9.1 ± 1.07 8.4-9.9
C 10 12.6 ± 4.43 5.8-19.9
Total 31 7.21 ± 4.72 2.6-19.9
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Predictors of early mortality and morbidity following surgical 
palliation of malignant pleural effusion
Pilling, John; Dusmet, Michael; Ladas, George; Goldstraw, Peter 
Royal Brompton Hospital, London, UK
Background: There is little evidence to identify which patients being 
considered for surgical palliation of malignant pleural effusion (MPE) 
are at high risk of death or serious complications. We evaluated our 
experience to identify prognostic factors.
Methods: We reviewed 304 consecutive patients [188 female, median 
age 60 years (range 26-90)] who underwent 337 procedures for pallia-
tion of MPE over a 72 month period. Procedures performed included 
thoracoscopic talc pleurodesis 214, pleuroperitoneal shunt insertion 41, 
intercostal drainage and pleurodesis under local anaesthetic 40, pleural 
biopsy alone 30 and long term pleural drainage 10. The commonest 
malignancies were breast (32%), mesothelioma (24%), lung (15%) and 
ovary (9%). 
Results: Hospital mortality was 4.3%; complication rate 17% and 30 
day mortality 11.2%. Hypoalbuminaemia (p=0.003) and raised alanine 
transaminase (ALT) (p=0.004) were associated with increased hospital 
mortality on univariate analysis. On multivariate analysis hypoalbu-
minaemia maintained signiﬁcance (p=0.04). Post operative complica-
tions were associated with a preoperative diagnosis of malignancy 
(p=0.03) on univariate analysis. No factor maintained signiﬁcance 
on multivariate analysis. Thirty day mortality was associated with 
preoperative diagnosis of malignancy (p=0.028), short duration of 
symptoms (p=0.042), hypoxaemia (p=0.006), leucocytosis (p<0.001), 
hypoalbuminaemia (p<0.001), raised ALT (p<0.001) and poor perfor-
mance status (p=0.014) on univariate analysis. Leucocytosis (p=0.014), 
hypoalbumiaemia (p=0.001) and raised ALT (p=0.032) maintained 
signiﬁcance on multivariate analysis.
  Hospital Mortality
30-day  
Mortality
Complications
WCC >12 4 of 55 (7.3%) 15 of 52 (29%) 7 of 55 (13%)
 <12 11 of 277 (3.9%) 23 of 248 (9.3%) 59 of 277 (21%)
Albumin <35 15 of 222 (6.8%) 37 of 197 (19%) 44 of 222 (20%)
 >35 0 of 109 (0%) 1 of 102 (0.98%) 22 of 109 (21%)
ALT <41 8 of 269 (2.9%) 23 of 241 (9.5%) 50 of 269 (18%)
 >41 7 of 51 (14%) 15 of 48 (31%) 11 of 51 (21%)
Conclusions: Hypoalbuminaemia is a marker of generalized physi-
ological impairment; it is associated with increased mortality both in 
hospital and at 30 days. Its presence should inﬂuence risk assessment, 
treatment decisions and discussions with the patient.
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Background: Thymic epithelial tumors (TETs), the most common 
tumor of the anterior mediastinum, are epithelial neoplasms of the 
thymus with a wide spectrum of morphologic features. 
Methods: We retrospectively analyzed clinical features of TET and 
the correlation of WHO histologic classiﬁcation and Masaoka staging 
system with different treatment modalities in 195 patients, from 1995 
to 2005. 
Results: According to the Masaoka’s staging system, there were 78 
(40.0 %) patients with stage I, 38 (19.5%) with stage II, 41 (21.0%) 
with stage III, 38 (19.5%) with stage IV. All patients were re-classi-
ﬁed according to the WHO criteria as follows: Type A (n=9, 4.6%), 
AB (n=37, 18.9%), B1 (n=29, 14.8%), B2 (n=48, 24.6%), B3 (n=40, 
20.5%), C (n=32, 16.4%). There was a fairly good correlation between 
Masaoka staging and WHO histotype (P<0.05). However, in multivari-
ate analysis, the tumor stage and WHO histotype were two independent 
factors separately for predicting overall survival (P <0.001, P <0.001, 
respectively). Thus, both Masaoka stage and WHO histotype should 
be considered in risk stratiﬁcation of therapy for TET patients. Patients 
with completely resected type B2, B3 and C and adjuvant radiotherapy 
(n=57) had more favorable disease-free and overall survival as com-
pared with those without adjuvant treatment (n=20) (P=0.015, 0.015, 
respectively). Given that the predominant sites of recurrence after 
surgery was pleura/pericardium and lung, and the fact that complete re-
section was a signiﬁcant inﬂuential factor for survival at log-rank test, 
an active investigation of newer treatment strategies such as neoadju-
vant treatment to improve the resectability and development of optimal 
adjuvant treatment modality is a high priority especially for those with 
high-risk for recurrence or in patients with advanced stage disease.
Conclusions: Though there was a clear association between the two 
systems the Masaoka stage and WHO histotype were two independent 
prognostic factors for survival. Despite of some discordance between 
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the two systems, the two parameters, therefore, should both be consid-
ered during decision-making for therapeutic approaches.
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High-resolution ROMA analysis of chromosomal rearrangements 
in mesothelioma patients with poor and good survival
Ivanov, Sergey V.1 Ivanova, Alla V.1 Lucito, Robert2 Pass, Harvey I.13 
1 NYU School of Medicine, New York, NY, USA 2 Cold Spring Harbor 
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Background: Representational oligonucleotide microarray analysis 
(ROMA) is a recently developed microarray-based high-resolution 
technology that helps linking chromosomal losses and gains with 
speciﬁc genetic events. ROMA identiﬁes the boundaries of deletions, 
duplications, and ampliﬁcations with the accuracy of roughly 50-100 
kb throughout the whole human genome. Mesothelioma is an aggres-
sive asbestos-related cancer with short (median 11-22 months) survival 
and poorly investigated genetic components. 
Methods: We performed ROMA on DNAs isolated from mesothelioma 
patients to assess the possible link between chromosome rearrange-
ments and prognosis and to identify the critical chromosomal events 
involved in the disease progression. Analysis of the signal intensity 
data obtained with microarray that contained more than 40,000 features 
was performed using CGH-Explorer software. 
Results: A remarkably high rate of losses and gains on the sub-chro-
mosomal level was reported in the patients with poor survival. The 
most frequent events in the long survivors were losses of chromosomes 
1, 4p, 6q, 9, 10, 14-22 and gains of chromosomes 12 and 13. The 
comparison between two groups of patients helped to identify “early” 
chromosomal events and genes that may play critical roles in mesothe-
lioma progression. 
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Health related quality of life, mood disorders and coping abilities 
in an unselected sample of patients with primary lung cancer.
Rolke, Heidi B.1 Bakke, Per S.2 Gallefoss, Frode1 
1 Dept. of Pulmonology, Sorlandet Hospital, Kristiansand S, Norway 2 
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Background: Health related quality of life (HRQoL) and mood disor-
ders have previously been evaluated only in selected patients with pri-
mary lung cancer, for example alongside chemotherapy studies or after 
lung surgery. The aims of this study were therefore to assess HRQoL 
and mood disorders, as well as coping abilities, in an unselected sample 
of patients with primary lung cancer, and test the associations between 
them and performance status (Eastern Cooperative Oncology Group, 
ECOG).
Methods: A questionnaire-based prospective study of all patients diag-
nosed with primary lung cancer in Southern Norway from June 14th, 
2002 to June 13th, 2005. HRQoL was assessed according to European 
Organization for Research and Treatment of Cancer (EORTC) Quality 
of Life Questionnaires (QLQ C30 and LC13 (the lung speciﬁc module); 
for both, a high symptom or function score indicates a low or high 
HRQoL, respectively), anxiety and depression according to Hospital 
Anxiety and Depression scale (HAD) and coping ability according to 
Sense of Coherence 13 (SoC) (13 indicating lowest coping ability and 
91 the highest).
Results: According to EORTC the function scores for global QoL, role 
and cognitive varied between 49,4 (mean, SDplusmn26), 41,1 (38) and 
77,3 (27). Correspondingly, symptom scores ranged from 52,7 (31) 
for fatigue, dyspnoea 52,3 (34) to haemoptysis 6,7 (18). There were 
no differences between NSCLC and SCLC except for fatigue and sore 
mouth, being more pronounced in SCLC 60,6, (31) than in NSCLC 
50,7 (35) and 7,6 (21) versus 15,6 (31), respectively (p’s<0,05). These 
scores are poorer than recorded in EORTC databases from chemothera-
py and radiotherapy studies.
According to HAD, 17% of patients scored compatible with anxi-
ety and 14% with depression. Seven percent scored consistent with 
combined anxiety and depression. Mean SoC score was 58,3 (SD 7). A 
HAD-score compatible with anxiety or depression was associated with 
signiﬁcantly poorer HRQoL scores. The Odds Ratio for depression was 
4 in cases of poor performance status (ECOG) 3-4 compared to ECOG 
0-2. A reduced coping ability was associated with anxiety (p=0,025, 
95%CI 0,39 - 5,70) and depression (p=0,035, 95%CI 0,24 - 6,60). 
Conclusion: In this survey on unselected patients with newly diag-
nosed lung cancer, mean HRQoL scores were poorer than reference 
values from previous, treatment-based studies. Patients with HAD 
scores compatible with depression and/or anxiety, percept more 
symptoms and report reduced quality of life at the time of diagnosis 
compared with patients without mood-related disorders. Anxiety and 
depression are also associated with lower coping abilities.
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Research priorities in non-small-cell lung cancer (NSCLC): 
recommendations of the Scientific Leadership Council (SLC) 
in Lung Cancer of the Coalition of Cancer Cooperative Groups 
(CCCG)
Schiller, Joan H. 
UT Southwestern Medical Center, Dallas, TX, USA
Background: While many potentially revolutionary therapies are being 
developed for NSCLC, the leading cause of cancer-related death in 
the US, advances are being made in screening and staging technology. 
Focused, consensus-based recommendations of research priorities, em-
